Quantcast

Latest Vancomycin Stories

2010-04-21 09:00:00

EXTON, Pa., April 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2010 are expected to be released on Wednesday, April 28, 2010 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2010 first quarter financial results and other business. The press release and the...

2010-04-11 14:17:15

Researchers identify the specific mechanism that triggers resistance to vancomycin A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections. Gerry Wright, a professor in the Department of Biochemistry and Biomedical Sciences at McMaster University in collaboration with colleagues at the John Innes...

2010-03-22 09:00:00

NEW YORK, March 22 /PRNewswire/ -- Recent clinical tests demonstrate that antimicrobial copper is effective in significantly reducing the bacterial load in intensive care unit (ICU) patient rooms and on many individual objects in those rooms. Results from a U.S. Department of Defense-funded clinical trial assessing the ability of antimicrobial copper to reduce the amount of bacteria on surfaces commonly found in hospital rooms were reported on at the Fifth Decennial International...

2010-03-19 07:45:00

FLORENCE, Italy and EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of two abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy. Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents....

2010-03-17 08:00:00

WALTHAM, Mass., March 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs). Clinical data and the opinions of interviewed thought leaders indicate that current and emerging...

2010-03-16 08:30:00

EXTON, Pa., March 16 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its investor day event, focusing on Cinryze growth opportunities on Friday, March 19, 2010. Lectures will be provided by a number of ViroPharma representatives. The investor day, entitled "Cinryze: Expanding the Global Opportunity," will be held from 9:00 A.M. until NOON Eastern Time on Friday, March 19, 2010. Among the topics...

2010-03-15 07:00:00

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including...

2010-03-12 07:00:00

TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and gram-negative bacteria and atypical pathogens. Importantly, nemonoxacin possesses activities...

2010-03-11 13:03:00

DURHAM, N.C., March 11 /PRNewswire/ -- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the launch of the first Food and Drug Administration (FDA) cleared chromID(TM) VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in...

2010-03-02 15:15:00

EXTON, Pa., March 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Cowen and Company 30th Annual Healthcare Conference at 11:05 A.M. ET on Tuesday, March 9, 2010. The conference is being held at the Boston Marriott Copley Place. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.